Programs
Powered by the invention of our revolutionary new class of medicines, we are developing innovative treatments for cancers with high unmet medical needs.

Programs

Powered by the invention of our revolutionary new class of medicines, we are developing innovative treatments for cancers with high unmet medical needs.

Bicycle Conjugates

Our Bicycle conjugates, including both toxin conjugates and targeted innate immune activators, are designed to rapidly deliver drugs systemically. The toxin conjugates deliver toxin payloads into solid tumors, while the targeted innate immune activators are designed to precisely target local immune activation within tumors without activating the immune system in bystander normal tissues, avoiding the need for direct tumor injection. These conjugates have favorable pharmacokinetic characteristics that provide extensive tissue penetration and a pronounced pharmacodynamic effect with a short duration of systemic exposure. Bicycles are excreted by the kidney (rather than the liver) and have shown no signs of immunogenicity to date. Together, these attributes support a favorable toxicological profile to control damage to normal tissue.

Learn More

Immune Oncology

Strategies that activate cytotoxic T-cells, a type of cell used in a body’s immune response, have been observed to improve outcomes in cancer. We believe that Bicycles represent a differentiated approach to target these T-cells that may confer several advantages over existing modalities due to the multivalency and pharmacokinetic characteristics of Bicycles. Our Bicycle T-cell modulators are designed to circumvent the limitations of antibody and biologic therapies, such as liver toxicity and limited efficacy, and to better enable combination therapy. The modular nature of Bicycles allows us to optimize therapeutic molecules for specific targets. 

We have identified potent Bicycle activators of multiple tumor necrosis factor (or TNFR family) receptors, including CD137 – a receptor that activates T-cells, in an effort to better enable combination therapy. In preclinical studies, we have linked these TNFR binding Bicycles to a range of tumor antigen targeting Bicycles to construct bi-specific molecules and observed that these bi-specific molecules agonize the CD137 receptor only in the presence of cells that express the appropriate tumor antigen, effectively converting the tumor cell into the equivalent of an antigen presenting cell.

Learn More

Bicycle Conjugates

Discovery
Preclinical
Clinical
MT1 Program (BT1718)
Clinical
EphA2 (BT5528) Program
Clinical
Nectin-4 (BT8009) Program
Discovery
TLR Agonist, STING Programs
Discovery

IMMUNE ONCOLOGY

Discovery
Preclinical
Clinical
CD137 Program
Discovery
CD137 Bi-specific Programs
Discovery